BETA – Welcome to our new website. It is a work in progress, your feedback will help us to improve it.

This website uses cookies

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.

Aurum Biosciences

Aurum Biosciences

Aurum Biosciences is a clinical-stage biopharmaceutical company developing novel therapeutics and diagnostics in areas of unmet clinical need. Its patented ABL-101 platform technology represents the first major advancement in the management of acute stroke patients in the past 20 years. The technology is being developed in other clinical indications such as inflammatory conditions, oncology, cardiovascular conditions, spinal cord injury and dementia.


Aurum Biosciences is a 2015 spin-out company of NHS Greater Glasgow and Clyde, University of Glasgow and InnoScot Health.